In and exclusion criteria
Inclusion criteria:
- Diagnosis of primary esophageal adenocarcinoma or squamous cell carcinoma (cT1b-4a, N0-3, M0)
- in the mid or distal esophagus or at the level of the gastroesophageal junction
- scheduled for undergoing transthoracic esophagectomy with curative intent or for esophageal reconstruction with a gastric or jejunal interposition.
- Age ≥ 18 years,
- Able to give written informed consent
Exclusion criteria:
- Patients planned for rescue surgery,
- Patients planned for colonic interposition,
- Known or suspected pregnancy,
- Patients who have undergone upper GI surgery within 30 days before randomization,
- Unable to understand the study information, study instructions and give informed consent.
- Patients enrolled in a trial that would interact with the intervention,
- Patients with a known allergy, sensitivity, or interaction to components of the investigational medicinal product,
- Patients with known/documented colonization of Enterobacteriaceae and or Pseudomonas Aeruginosa that are resistant to both tobramycin/gentamicin and to carbapenem antibiotics,
- Patients undergoing CVVH,
- Patients with documented chronic renal failure (GFR < 15 mls/min) or who are on chronic intermittent hemo- or peritoneal dialysis,
- Women of childbearing potential at risk of pregnancy, not using adequate contraception,
- Patients with the inability to swallow the SDD,
- Patients with pre-existing degenerative neuromuscular diseases like, but not limited to, myasthenia gravis or Parkinson disease).